References
Haass, C. & Selkoe, D. J. Cell 75, 1039–1042 (1993).
Vassar, R. et al. Science 286, 735–741 (1999).
Hussain, I. et al. Mol. Cell. Neurosci. www.academicpress.com/www/journal/cn/mcne
Yan, R. et al. Nature 402, 533–537 (1999).
Sinha, S. et al. Nature 402, 537–540 (1999).
Price, D. L. et al. Annu. Rev. Genet. 32, 461–493 (1998).
Drews, J. Nature Biotechnol. 14, 1516–1518 (1996).
Ren, S. & Lien, E. J. Prog. Drug Res. 51, 3–31 (1998).
Lichtenthaler, S. F. et al. Proc. Natl Acad. Sci. USA 96, 3053–3058 (1999).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
De Strooper, B., König, G. A firm base for drug development. Nature 402, 471–472 (1999). https://doi.org/10.1038/44973
Issue Date:
DOI: https://doi.org/10.1038/44973
- Springer Nature Limited
This article is cited by
-
Alzheimer’s disease in people with Down’s syndrome: the prospects for and the challenges of developing preventative treatments
Journal of Neurology (2017)
-
Developing consensus 3D-QSAR and pharmacophore models for several beta-secretase, farnesyl transferase and histone deacetylase inhibitors
Journal of Molecular Modeling (2012)
-
SPF-5506-A4, a New Peptaibol Inhibitor of Amyloid β-Peptide Formation Produced by Trichoderma sp.
The Journal of Antibiotics (2007)
-
Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease
Journal of Molecular Neuroscience (2002)